Etoposide
- PDF / 169,320 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 93 Downloads / 199 Views
1
S
Interstitial lung diseases and exacerbation of idiopathic interstitial pneumonia: 2 case reports In a retrospective study of 122 patients treated between 2008 and 2017, 2 patients [ages and sexes not stated] were described, who developed interstitial lung diseases (1 patient) or experienced exacerbation of idiopathic interstitial pneumonia (1 patient) during treatment with etoposide for small cell lung cancer [routes, dosages, time to reactions onsets not stated]. Both the patients received treatment with unspecified corticosteroids [outcomes not stated]. Author comment: In the study, the incidence of chemotherapy-induced [Interstitial lung diseases] development/[idiopathic interstitial pneumonia] exacerbation in patients with [idiopathic pulmonary fibrosis] was significantly higher than that in other patient groups. Koyama N, et al. Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation. PLOS One 14: e0221718, No. 8, Aug 2019. Available from: URL: http://doi.org/10.1371/ 803439464 journal.pone.0221718 - Japan
0114-9954/19/1783-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Dec 2019 No. 1783
Data Loading...
